These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30853674)

  • 21. Letter: optimising response to ustekinumab therapy for patients with Crohn's disease.
    Hudson J; Herfarth HH; Barnes EL
    Aliment Pharmacol Ther; 2020 Sep; 52(5):906. PubMed ID: 32852815
    [No Abstract]   [Full Text] [Related]  

  • 22. Letter: ustekinumab for the treatment of post-surgical and refractory Crohn's disease.
    Tursi A; Mocci G; Picchio M; Elisei W; Maconi G
    Aliment Pharmacol Ther; 2021 Apr; 53(7):859-860. PubMed ID: 33709395
    [No Abstract]   [Full Text] [Related]  

  • 23. Infliximab vs Ustekinumab in Biologic Naive Crohn's Disease.
    Huang X; Li X
    Clin Gastroenterol Hepatol; 2022 May; 20(5):e1216. PubMed ID: 33991689
    [No Abstract]   [Full Text] [Related]  

  • 24. Letter: optimising response to ustekinumab therapy for patients with Crohn's disease-author's reply.
    Kopylov U
    Aliment Pharmacol Ther; 2020 Sep; 52(5):907. PubMed ID: 32852835
    [No Abstract]   [Full Text] [Related]  

  • 25. An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients.
    Kawalec P; Moćko P
    J Comp Eff Res; 2018 Feb; 7(2):101-111. PubMed ID: 29115855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world Short-term Effectiveness of Ustekinumab in Crohn's Disease: Results from a Multicenter, Prospective Study in China.
    Cao Q; Chen C; Gao X; Chen Y; Hu N; Liang J; Wu K
    Inflamm Bowel Dis; 2022 Jun; 28(Suppl 2):S42-S44. PubMed ID: 35442448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ustekinumab for treatment of cutaneous Crohn's disease.
    Abdat R; Markova A; Farraye FA; Lichtman MK
    Dermatol Online J; 2016 Oct; 22(10):. PubMed ID: 28329588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.
    Deepak P; Sandborn WJ
    Gastroenterol Clin North Am; 2017 Sep; 46(3):603-626. PubMed ID: 28838418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab.
    Harris KA; Horst S; Gadani A; Nohl A; Annis K; Duley C; Beaulieu D; Ghazi L; Schwartz DA
    Inflamm Bowel Dis; 2016 Feb; 22(2):397-401. PubMed ID: 26752468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease.
    Van den Berghe N; Verstockt B; Vermeire S; Thomas D; Declerck P
    Clin Gastroenterol Hepatol; 2023 Mar; 21(3):838-840.e2. PubMed ID: 34942369
    [No Abstract]   [Full Text] [Related]  

  • 31. Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth?
    Liu K; Cai F; Huang J
    Aliment Pharmacol Ther; 2020 Oct; 52(7):1253-1254. PubMed ID: 33016544
    [No Abstract]   [Full Text] [Related]  

  • 32. [A case of Crohn's disease complicated by Guillain-Barrè syndrome during ustekinumab therapy].
    Fukushima T; Nakajima K; Nozawa H; Nishino H; Sugita A; Koganei K; Futatsuki R; Yamaguchi S; Asano S; Matsushima M
    Nihon Shokakibyo Gakkai Zasshi; 2019; 116(4):324-329. PubMed ID: 30971669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on ustekinumab for the treatment of Crohn's disease.
    Leung Y; Panaccione R
    Gastroenterol Clin North Am; 2014 Sep; 43(3):619-30. PubMed ID: 25110262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth. Authors' reply.
    Biemans VBC; Hoentjen F; Pierik MJ
    Aliment Pharmacol Ther; 2020 Oct; 52(7):1255-1256. PubMed ID: 33016547
    [No Abstract]   [Full Text] [Related]  

  • 35. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
    Aliyev ER; Hay JW; Hwang C
    Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positioning Ustekinumab in Crohn's Disease: From Clinical Evidence to Clinical Practice.
    Danese S; Bonovas S; Peyrin-Biroulet L
    J Crohns Colitis; 2017 Oct; 11(10):1258-1266. PubMed ID: 28575273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Letter: potential selection bias in the real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease.
    Adomi M; Ray A
    Aliment Pharmacol Ther; 2022 Apr; 55(8):1069. PubMed ID: 35362122
    [No Abstract]   [Full Text] [Related]  

  • 38. Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease.
    Restellini S; Khanna R; Afif W
    Inflamm Bowel Dis; 2018 Sep; 24(10):2165-2172. PubMed ID: 29788272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply.
    Selinger CP; Lenti MV; De Silvestri A
    Aliment Pharmacol Ther; 2022 Apr; 55(8):1070-1071. PubMed ID: 35362123
    [No Abstract]   [Full Text] [Related]  

  • 40. The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.
    Khanna R; Chande N; Vermeire S; Sandborn WJ; Parker CE; Feagan BG
    Inflamm Bowel Dis; 2016 Jul; 22(7):1737-43. PubMed ID: 27306074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.